伊曲康唑治疗儿童头癣36例临床观察

目的：观察伊曲康唑对儿童头癣的疗效及安全性。方法：口服伊曲康唑100mg每日1次，连服6周。结果：36例患儿完成疗程时痊愈25例，显效8例；停药4周后，痊愈31例，显效3例，总有效率94.4%。结论：伊曲康唑治疗儿童头癣疗效显。     

伊曲康唑治疗头癣24例临床观察

为观察伊曲康唑对头癣,尤其是对儿童头癣的疗效有恶性循环,随访了24例用伊曲康唑治疗的头癣患者,其中儿童21例,成人3例。均口服伊曲康唑每日1次共6周,儿童为100mg/d,成人200mg/d。结果经6周治疗,痊愈16例,显效5例;停药4周后,痊愈20例,显效3例,好转1例,总有效率95．8％。     

伊曲康唑4周疗法治疗儿童头癣128例临床疗效观察

目的：了解伊曲康唑治疗儿童头癣的疗效与安全性。方法：采用伊曲康唑治疗128例头癣患儿，4岁以上的剂量为100mg／d，4岁以下剂量为50mg／d，晚餐后服用，连续服用4周。结果：128例患儿在疗程结束后4周的痊愈率为80．47％。所有患儿服药期间均未出现不良反应。结论：伊曲康唑4周疗法治疗儿童头癣疗效确切，安全性好。     

伊曲康唑与特比萘芬治疗儿童头癣疗效观察

目的:寻找治疗儿童头癣有效、安全的方法。方法:应用伊曲康唑治疗儿童头癣27例,特比萘芬治疗儿童头癣25例,并作疗效与真菌清除率观察。结果两种药物在用药8周以上的总有效率无明显差异,但伊曲康唑于用药第4周与第6周时疗效存在显著性差异,而特比萘芬在用药第6周与第8周时疗效存在显著性差异。结论:伊曲康唑与特比萘芬对治疗儿童头癣都是有效安全的,但伊曲康唑疗程需达6周,而特比萘芬疗程需达8周;伊曲康唑6周时达到真菌清除;而特比萘芬需达8周。     

伊曲康唑与氟康唑治疗66例复发性念珠菌阴道炎疗效比较

目的：了解应用伊曲康唑与氟康唑治疗复发性念珠菌阴道炎的临床疗效。方法：66例临床确诊为念珠菌阴道炎,随意分类两组：伊曲康唑组：200mg,每日一次,连续3天为一疗程,氟康唑组：100mg,每日一次,连续3天为一疗程,两组均连续治疗三个月共3个疗程。结果：伊曲康唑组,治疗后1、4、8、12周的总有效率分别为：85．3％、88．2％、91．2％、91．2％,氟康唑组治疗后1、4、8、12周的总有效率分别为81．3％、87．5％、78．1％、75．0％。治疗后1、4、8、12周两种药物治疗的总有效率相比差异无显性（P＞0．05）,但伊曲康唑治疗后第8、12周的复发率远低于氟康唑治疗组。结论：伊曲康唑与氟康唑治疗复发性念珠菌阴道炎均有较好的疗效,其远期疗效伊曲康唑优于氟康唑。     

伊曲康唑与灰黄霉素治疗儿童头癣的随机双盲对比研究

最近已有报道用伊曲康唑治疗由犬小孢子菌所致的头癣有效。为进一步观察伊曲康唑的安全性和副作用,对伊曲康唑与灰黄霉素治疗头癣进行了双盲对比观察。 材料和方法:按随机双盲法将患者分成两组,分别与食物同时口服伊曲康唑100mg/d或灰黄霉素500mg/d,共6周。在治疗开始及治疗第2、4、6周和治疗结束后第2、4、8周进行临床评分和真菌学检查。治疗结束后第4、8周进行总的疗效评估。伊曲康唑组18例,女6例,男12例,除1例为成人外其余年龄均小于12岁;     

伊曲康唑治疗花斑癣临床疗效观察

目的：评价伊曲康唑治疗花斑癣的疗效与安全性。方法：采用开放性试验，伊曲康唑200mg/d，饭后口服，连服7d。观察了可供疗效评价的30例花斑癣患。结果：临床治愈率为80．00％，临床有效率为100．00％；真菌学治愈率为90．00％。总治愈率为73．30％，总有效率为90．00％。不良反应发生率为3．30％。结论：伊曲康唑治疗花斑癣疗效确切，安全性好。     

伊曲康唑治疗掌跖脓疱病临床观察

目的：观察伊曲康唑治疗掌跖脓疱病的临床疗效及安全性。方法：对30例掌跖脓疱病患者给予口服伊曲康唑100mg／d，服用4周后减量至100mg隔日1次，再服用4周，并观察疗效及安全性。停药后随访8周。结果：30例患者中显效20例，好转7例，无效3例。随访至第8周时有12例复发，但复发频率及程度均较治疗前明显降低。未见明显不良反应。结论：伊曲康唑治疗掌跖脓疱病安全有效。     

伊曲康唑治疗头癣11例报告

伊曲康唑治疗头癣１１例报告张益珠①黄一锦①我们于１９９４年４月～１９９７年２月应用杨森制药有限公司生产的伊曲康唑治疗头癣１１例，取得满意的疗效，现报告如下。１临床资料和方法１．１一般资料：１１例头癣患者中男３例，女８例；年龄最小５岁，最大２０岁，平均...     

伊曲康唑与达克宁栓联合治疗阴道念珠菌病662例疗效观察

目的：观察伊曲康唑联合达克宁栓治疗阴道念珠菌病的临床疗效。方法：选择单纯患阴道念珠菌病患662例，给予联合疗法，1周、4周、8周、12周复查。结果：662例患中痊愈650例占98．2％；有效12例，占1．8％；无效0例，总有效率100％。结论：二联疗法治疗阴道念珠菌病，对近、远期疗效都很满意。     

1%环吡酮胺软膏治疗浅部真菌病的疗效观察

目的 :评价环吡酮胺软膏治疗皮肤浅部真菌病的疗效和安全性。方法 :1 3 0例浅部真菌病分成二组 ,治疗组外用环吡酮胺软膏 ,对照组外用特比萘芬乳霜 ,体股癣疗程 2周 ,手足癣疗程 4周。结果 :治疗组 66例中治愈 42例 ,显效 1 8例 ,临床总有效率 90 91 % ,真菌清除率 89 3 9% ;对照组总有效率为 92 1 9% ,真菌清除率为 90 63 % ,两组疗效差异无显著性 (P >0 0 5 )。结论 :环吡酮胺软膏治疗皮肤浅部真菌病疗效显著且安全     

The use of itraconazole to treat cutaneous fungal infections in children

BACKGROUND: Cutaneous mycoses such as tinea capitis, onychomycosis and some cases of tinea corporis/cruris, and tinea pedis/manus require oral antifungal therapy. There is relatively limited data regarding the use of the newer oral antifungal agents, e.g. itraconazole, in the treatment of these mycoses in children. OBJECTIVE: We wished to determine the efficacy and safety of itraconazole continuous therapy in the management of cutaneous fungal infections in children. METHODS: Children with cutaneous mycoses were treated with itraconazole in an open-label manner in 4 studies. For tinea capitis, the treatment regimens using itraconazole continuous therapy were: study 1, 3 mg/kg/day for 4 or 8 weeks; study 2, 5 mg/kg/day for 6 weeks, and study 3, 5 mg/kg/ day for 4 weeks. In a different trial, study 4, itraconazole continuous therapy 5 mg/kg/day was used to treat toenail onychomycosis (duration: 12 weeks), tinea corporis/ cruris (duration: 1 week) and tinea pedis/manus (duration: 2 weeks). RESULTS: The efficacy rates at follow-up 12 weeks from the start of therapy in children with tinea capitis treated using the itraconazole continuous regimen were: clinical cure (CC) and mycological cure (MC) in study 1 (n = 10, Trichophyton violaceum all patients), CC 50%, MC 86%; in study 2 (n = 35, Microsporum canis 22 patients, Trichophyton sp. 12 patients), CC 82.8%, MC 80%, and in study 3 (n = 16, M. canis 11 patients, Trichophyton sp. 5 patients), (CC 66.7%, MC 78.5%. Itraconazole was also effective in the treatment of dermatomycoses in 24 children (study 4). The CC and MC rates at the follow-up 8 weeks from the start of therapy in children with dermatomycoses and 12 months in children treated for onychomycosis were: onychomycosis (n = 1, T. rubrum), CC 100%, MC 100%; tinea corporis (n = 12, M. canis 10 patients), CC 100%, MC 90%; tinea cruris (n = 3, Trichophyton sp. 2 patients), CC 100%, MC 100%; tinea manus (n = 1, T. rubrum), CC 100%, MC 100%, and tinea pedis (n = 7, T. rubrum), CC 100%, MC 100%). Adverse effects consisted of a cutaneous eruption in 1 (1.2%) of the 85 children, with mild, transient, asymptomatic elevation of liver function tests (less than twice the upper limit of normal) in 2 (3.4%) of 58 children in whom monitoring was performed. CONCLUSIONS: Itraconazole is effective and safe in the treatment of tinea capitis and other cutaneous fungal infections in children.     

口服特比萘芬与伊曲康唑治疗儿童头癣的疗效比较

目的比较口服特比萘芬与伊曲康唑治疗儿童头癣的疗效。方法 2021年1-12月北京儿童医院皮肤科门诊头癣患儿53例, 采用随机数字表法分为特比萘芬治疗组(体重< 20 kg, 剂量62.5 mg/d;体重20 ～ 40 kg, 剂量125 mg/d;体重> 40 kg, 剂量250 mg/d)和伊曲康唑治疗组(3 ～ 5 mg·kg-1·d-1)。使用SPSS23.0软件进行统计分析, 组间计数资料比较采用χ2检验或Fisher确切概率法。结果特比萘芬治疗组27例(白癣17例、脓癣10例), 治愈14例(51.85%), 其中白癣5例, 脓癣9例。伊曲康唑治疗组26例(白癣17例、脓癣9例), 治愈25例(96.15%), 其中白癣16例, 脓癣9例。伊曲康唑组的疗效显著高于特比萘芬组, χ2 = 13.37, P < 0.001。结论伊曲康唑治疗儿童白癣的效果优于特比萘芬, 但两药治疗儿童脓癣的疗效相当。     

Once weekly fluconazole is effective in children in the treatment of tinea capitis: a prospective, multicentre study

In an open, multicentre evaluation carried out in Brazil, Canada and South Africa we have demonstrated that fluconazole 8 mg kg-1 once weekly is effective in tinea capitis caused by Trichophyton and Microsporum species. There were 61 children, aged (mean +/- SE) 5.0 +/- 0.3 years; weight (mean +/- 5.6) 20.0 +/- 0.9 kg; 41 males, 20 females; one Asian, 57 Black, one Caucasian and two Hispanic. The organisms were Trichophyton violaceum (33 patients), T. tonsurans (11) and Microsporum canis (17). The extent of tinea capitis at pretherapy was: mild (18 patients), moderate (30) and severe (13). Patients with tinea capitis due to Trichophyton species were initially treated for 8 weeks with an extra 4 weeks of fluconazole if clinically indicated. All 44 patients with tinea capitis due to Trichophyton species were completely cured (clinically and mycologically) when evaluated 8 weeks after completion of active treatment, following 8 weeks of once weekly dosing in 35 patients and 12 weeks of once weekly dosing in nine patients. In Microsporum canis tinea capitis, an extra 4 weeks was administered at week 12 in patients where it was clinically indicated at the time. Sixteen of 17 patients with M. canis tinea capitis were completely cured (clinically and mycologically) when evaluated 8 weeks following the end of treatment when given for 8, 12 and 16 weeks in 12, one and three patients, respectively. Overall, complete cure (clinical and mycological) occurred in 60 of 61 patients at follow-up 8 weeks from the end of therapy. The duration of once weekly fluconazole in the 60 patients was 8 weeks (47 patients), 12 weeks (10 patients) and 16 weeks (three patients), respectively. Clinical adverse effects consisted of a mild, reversible gastrointestinal complaint in three (4.9%) of 61 children. A laboratory abnormality with elevated liver function tests was observed in one (5.9%) of 17 patients; this was asymptomatic, and reversible. No patient discontinued therapy. The data suggest that once weekly fluconazole dosing is effective, safe and associated with high compliance when used to treat tinea capitis.     

Successful treatment of tinea capitis with 2% ketoconazole shampoo

BACKGROUND: Oral antifungal drugs are required for effective treatment of tinea capitis. Topical antifungal shampoo's, namely ketoconazole 2% shampoo or products with selenium sulfide or salicylic acid are recommended as adjunctive therapy. Topical antifungal monotherapy has not been successful in the treated of tinea capitis. The purpose of this open study was to evaluate ketoconazole 2% shampoo as a monotherapy for the treatment of tinea capitis. METHOD: A total of 16 black children, aged 3-6, all with proven tinea capitis caused by Trichophyton tonsurans, were treated daily for 8 weeks with 2% ketoconazole shampoo for a total of 56 treatments. Clinical and mycologic examinations were performed every 2 weeks and again at 4 weeks following treatment. The number of colonies were counted on each plate after each visit. Patients with positive cultures after 8 weeks were placed on oral griseofulvin; those with negative cultures were followed monthly by culture for an additional 12 months. RESULTS: Marked clinical improvement occurred in all patients within 2 weeks and absence of pruritus was noted by the patients as early as 2-6 days. After 8 weeks of shampoo, 14 of the 15 (93%) children were clinically healed. Mycologically, the cultures dropped from a confluent growth of T. tonsurans to less than 100 colonies within 2 weeks; fewer than 50 at week 4 and 20 colonies or fewer after week 6. At 8 weeks of treatment the number of colonies remained at 20 or fewer. Six of the 15 children (40%) had negative cultures after 2, 4, and 6 weeks. One child relapsed at the first 4-week follow-up visit. Five of 15 (33%) of the children remained culturally negative for 12 months post-treatment. CONCLUSIONS: Ketoconazole 2% shampoo alone reduces the number of viable arthroconidia in children with tinea capitis thus reducing the transmissibility and contagious nature of the disease. Unexpectedly, complete cure was obtained in 5/15 (33%) of the children. The children remained clinically and mycologically clear as long as one year after treatment.     

Lack of Efficacy of 6-Week Treatment with Oral Terbinafine for Tinea Capitis Due to Microsporum canis in Children

Abstract: Twenty-two children aged 2 to 9 years with noninflammatory tinea capitis due to Microsporum canis were evaluated in an open clinical pilot study run from January 1994 to July 1995. Each child was given oral terbinafine according to body weight for 6 weeks. Mycologic evaluation was done at the end of treatment and after follow-up periods of 4 and 8 weeks. None of the patients achieved complete mycologic cure by the end of the treatment period. Four weeks later complete mycologic cure was established in nine patients, and on final evaluation in seven. The treatment was very well tolerated by all the children. No systemic adverse effects were noted. According to our data, a 6-week course of oral terbinafine is inadequate for tinea capitis due to M. canis in children. Further study is needed to determine the most appropriate duration of therapy.     

不同方案国产特比萘芬治疗头癣随机双盲比较研究

目的：评价国产特比萘芬治疗头癣的疗效及安全性,探索最佳给药方案。方法：头癣患者随机分成三组,Ａ组连服２周,Ｂ组连服４周,Ｃ组连服１周后间隔２周再连服１周,４周治疗中不口服特比萘芬时给安慰剂,按体重给药,于第８周末评价疗效及安全性。结果：７６例可评价患者分离的病原菌主要包括犬小孢子菌４８株（６２．３％）、须癣毛癣菌２４株（３１．２％）。于８周末评价时,治愈率分别为６４％、８８．９％和８３．３％。只见轻微副作用。结论：口服国产特比萘芬治疗头癣疗效高、安全性好、患者耐受性好,连服药１周间隔２周再连续服药１周,为我们的推荐方案。     

1%盐酸布替萘芬乳膏治疗浅部真菌病临床观察

目的：评价1％盐酸布替萘芬乳膏治疗浅部真菌病的临床疗效及安全性，并与1％联苯苄唑凝胶进行比较。方法：对83例浅部真菌病患者进行治疗，其中治疗组43例，外用1％盐酸布替萘芬乳膏，每日1次；对照组40例，外用1％联苯苄唑凝胶，每日1次，体股癣疗程2周，手足癣4周。分别于停药及停药2周时观察记录患者的临床表现及治疗效果。结果：1％盐酸布替萘芬乳膏和1％联苯苄唑凝胶临床疗效相似，停药时临床总有效率分别为90．7％和90．0％，真菌总清除率为93．0％和90．0％；停药2周时临床总有效率分别为97．7％和92．5％，真菌总清除率为100．0％和92．5％。不良反应少。结论：1％盐酸布替萘芬乳膏治疗浅部真菌病疗效显著且安全。     

Overview of the use of terbinafine (Lamisil®) in children

This review summarizes the efficacy and tolerability of terbinafine (Lamisil®) in the treatment of dermatophytoses in children. In six clinical studies, 152 children who received terbinafine were evaluable for efficacy and 196 were evaluable for tolerability. In these studies, terbinaline was used for between 1 and 28 weeks. The median treatment was 4 weeks, the duration of treatment in the tinea capitis studies. As a result of extensive experience in adults at doses of 10 mg/kg and less, and the overall pharmacokinetic profile in children, including the lower volume of distribution of terbinafine into lipophilic tissue, the use of a dose of 125 mg/day for children weighing 20–40 kg, and 62.5 mg/day in children weighing less than 20 kg, has been proposed. This dose was shown to be well tolerated and effective. For children weighing >40kg, the adult dose of 250mg is appropriate. Terbinafine was shown to be very effective (93% cured), in the treatment of children with tinea capitis, using a shorter treatment duration (4 weeks) than that usually employed with presently available antifungal drugs. It is also effective in children with various dermatophyte infections of the skin, with a cure rate of more than 90%. Terbinafine was shown to be well tolerated in children aged between 2 and 17 years. The recommended duration of treatment for tinea capitis is 4 weeks. The recommended duration of treatment for other skin or nail dermatophyte infections, based on extensive studies in adults, and confirmed in children, is 2 weeks for tinea corporis and tinea pedis, 6 weeks for finger-nail onychomycosis and 12 weeks for toe-nail onychomycosis.